Combretum laurifolium mart. extract and methods of extracting and using such extract

Abstract

A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.

1 . A method of inhibiting COX-2 in a subject in need thereof, comprising:
 administering a composition comprising a therapeutically effective amount of an extract of  Combretum laurifolium  Mart. to said patient.   
     
     
         2 . The method of  claim 1  wherein said composition further comprises a solvent selected from the group consisting of: a polar solvent; a non-polar solvent; a moderately polar solvent; and an aqueous solvent. 
     
     
         3 . The method of  claim 1 , wherein said a composition further comprises a compound selected from the group consisting of: 20-epi-isoiguesterinol, Salasol A, isoguesterin, nor-isoguesterin, and salacinol. 
     
     
         4 . The method of  claim 2 , wherein said solvent is non-polar and is selected from the group consisting of: methanol; ethyl-acetate; hexane; and water. 
     
     
         5 . A method of inhibiting NF-Kappa B in a subject in need thereof, comprising: administering a composition comprising a therapeutically effective amount of an extract of  Combretum laurifolium  Mart. to said patient. 
     
     
         6 . The method of  claim 5  wherein said a composition further comprises a solvent selected from the group consisting of: a polar solvent; a non-polar solvent; a moderately polar solvent; and an aqueous solvent. 
     
     
         7 . The method of  claim 5 , wherein said composition further comprises a compound selected from the group consisting of: 20-epi-isoiguesterinol, Salasol A, isoguesterin, nor-isoguesterin, and salacinol. 
     
     
         8 . The method of  claim 6 , wherein said solvent is non-polar and is selected from the group consisting of: methanol; ethyl-acetate; hexane; and water.